Lantheus seeks FDA OK for prostate PET imaging agent

By staff writers

September 30, 2020 -- Lantheus Medical Imaging submitted a new drug application to the U.S. Food and Drug Administration (FDA) for its PyL (F-18 DCFPyL) radiopharmaceutical.

PyL is a prostate specific membrane antigen-targeted small-molecule PET radiopharmaceutical that aims to provide a view of prostate cancer. Lantheus is requesting priority review of PyL, which may shorten the FDA's review time to six months until acceptance. Typically, the review takes 10 months.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking